Latest research on Lantus

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.

Latest findings

Treatment of rats and mice for up to 2 years at doses up to 10-times the normal starting dose of insulin glargine have not suggested an increase in carcinogenicity (Bolli and Owens 2000; Lantus 2004). [source, 2006]
In the IGlar/IDeg group, the basal insulin was switched after 4 weeks from IGlar (Lantus, SoloSTAR; Sanofi, Paris, France) to IDeg (Tresiba, FlexTouch; Novo Nordisk, Bagsvaerd, Denmark). [source, 2015]